Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer

Clin Cancer Res. 2016 Sep 1;22(17):4280-2. doi: 10.1158/1078-0432.CCR-16-1137. Epub 2016 Jun 21.

Abstract

Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ©2016 AACRSee related article by Yang et al., p. 4466.

Publication types

  • Letter

MeSH terms

  • Alternative Splicing
  • Androgen Receptor Antagonists / pharmacology
  • Androgen Receptor Antagonists / therapeutic use*
  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Male
  • Mice
  • Molecular Targeted Therapy*
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Prostatic Neoplasms, Castration-Resistant / genetics
  • Prostatic Neoplasms, Castration-Resistant / metabolism*
  • Protein Interaction Domains and Motifs / genetics
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism*

Substances

  • Androgen Receptor Antagonists
  • Antineoplastic Agents
  • Receptors, Androgen